HEPATITIS B VACCINEIt is a sterile suspension containing formaldehyde-inactivated hepatitis A virus (HM 175 hepatitis A virus strain) adsorbed onto aluminium hydroxide. The virus is propagated in MRC5 human diploid cells. An adult dose is standardised to ensure a viral antigen content of not less than 720 ELISA units of viral antigens, in a 1 ml dose volume. A paediatric dose is standardised to ensure a viral antigen content of not less than 360 ELISA units of viral antigens in a 0.5 ml dose volume.
Active immunisation against hepatitis A virus infection.
Adult: 1 ml/not less than 720 ELISA units. Paediatrics: 0.5 ml/not less than 360 ELISA units. Immunisation schedule: First dose at elected date and second one month later. If necessary, second dose may be administered a minimum of two weeks following the first dose. Booster dose is recommended at any time between 6 & 12 months after initiation of primary course. Vaccine should be used intramuscularly; and in deltoid regions in adult and children.
Acute severe febrile illness
Administer with caution to subjects with thrombocytopenia or a bleeding disorder. Should not be administered intravenously.
Mild headache, malaise, fatigue, fever, nausea and loss of appetite.
|Brand Name||Manufactured by|
|BIOVAC B||MERIND LIMITED|
|REVACE-B||BHARAT BIOTECH INTERNATIONAL LIMITED|